Avacopan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), CIPM (Spain) and G-BA (Germany), among others, recommended or restricted avacopan, while DMC (Denmark) and ZIN (Netherlands) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “In combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic …”, while PBAC (Australia) recorded not recommended for “Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA)”.
The record spans 4 years, opening at AWMSG (Wales) on 14 Apr 2022 and running to 2 Apr 2026.
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2024, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 11 of 16 records date from 2023 or later.
4 distinct indication wordings are recorded for avacopan by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess avacopan, on 14 Apr 2022; HIRA (South Korea) did not open a file until 2 Apr 2026 — a wide spread of 4 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
5 of the 11 agencies here assessed avacopan more than once, G-BA (Germany) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for avacopan.
The full ledger for avacopan reads 10 recommended, 3 not recommended, 1 no benefit and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 5 Mar 2026 | Tavneos — benefit assessment §35a | added benefit: not proven | source |
| PHARMAC (New Zealand) | 8 Dec 2025 | ANCA-associated vasculitis | PTAC advice: High | source |
| SMC (Scotland) | 13 Nov 2023 | In combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic … | accepted | source |
| DMC (Denmark) | 23 Aug 2023 | Tillægsbehandling til behandling af patienter med svær, aktiv granulomatose med polyangiitis (GPA) eller mikroskopisk po… | Ikke anbefalet | source |
| PBAC (Australia) | 2023 | Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA) | Not Recommended | source |
11 further decisions for avacopan, across 9 agencies, are not shown here. They include the most recent record on file, 2 Apr 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- siponimod — same ATC class L04 — Immunosuppressants
- darvadstrocel — same ATC class L04 — Immunosuppressants
- ublituximab — same ATC class L04 — Immunosuppressants
- gadopiclenol — also decided by HIRA in 2026Q2
- atezolizumab — also decided by HIRA in 2026Q2
- tenecteplase — also decided by HIRA in 2026Q2
Coverage: 16 decisions for avacopan from 11 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L04 — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.